Dalrada Cervical Cancer Testing Kit Study.
KEY TAKEAWAYS
Dalrada Corp (DFCO)
LIVE QUOTE
Dalrada’s ‘VIA’ Test Screening Kit Goes Head to Head with ‘Pap’ Smear Test Screening.
DALRADA aims to introduce its VIA Test kit to females in India - of which there is 497 million.
Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...
Mitesco Inc. Initiates “The Good Clinic” Rollout in Minneapolis; Introduces the Founders of “The...
MINNEAPOLIS, MN, Sept. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Mitesco, Inc. (OTCQB: MITI) today announced that The Good Clinic, LLC has filed...
American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.
Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has.
Potential...
There’s Simply No Loyalty Anymore.
TODAY'S LETTER
Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.
Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's...
Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!
Great headline, right?
The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
Adding American BriVision (ABVC) $3.30 to Stocks We Expect Double List. $7.00 Price Potential.
Adding to Our 2020 Biotech 5-Pack, 5 Stocks We Expect to Double in 2020